Patents Assigned to THERAPEUTICS, INC.
  • AKT1 modulators
    Patent number: 11999730
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: June 4, 2024
    Assignee: ALTEROME THERAPEUTICS, INC.
    Inventors: Michael David Bartberger, Elena V. Dneprovskaia, Yi Fan, Eric Anthony Murphy, Xuefeng Zhu
  • Compounds and methods of use
    Patent number: 11999727
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: June 4, 2024
    Assignee: Tango Therapeutics, Inc.
    Inventors: Kevin M. Cottrell, John P. Maxwell
  • Pyrazole derivatives
    Patent number: 11999718
    Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: June 4, 2024
    Assignee: APTABIO THERAPEUTICS INC.
    Inventors: Soo Jin Lee, Sung Hwan Moon, Sooho Ban, Eunsil Lee, Eun Jung Shin, Yoo-Kyung Goh
  • Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
    Patent number: 11999750
    Abstract: Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: June 4, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventor: Anantha Sudhakar
  • Anti-BCMA chimeric antigen receptors
    Patent number: 11999773
    Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: June 4, 2024
    Assignee: Cartesian Therapeutics, Inc.
    Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
  • Tetrahydropyridopyrimidine pan-KRas inhibitors
    Patent number: 11999753
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: June 4, 2024
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • Neuroactive steroids and their methods of use
    Patent number: 11999765
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: June 4, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20240174680
    Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
    Type: Application
    Filed: January 28, 2022
    Publication date: May 30, 2024
    Applicant: Cedilla Therapeutics, Inc.
    Inventors: Louise Clare KIRMAN, Carl Eric SCHWARTZ, Wojtek MICHOWSKI, Dale A. PORTER, JR., Justin RIPPER, John FEUTRILL, John Paul SHERRILL, Thomas P. BLAISDELL
  • COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASE
    Publication number: 20240173367
    Abstract: The invention provides compositions and methods for use in the treatment and prevention of cholestatic diseases.
    Type: Application
    Filed: May 17, 2023
    Publication date: May 30, 2024
    Applicant: Seres Therapeutics, Inc.
    Inventors: Madhumitha NANDAKUMAR, Alice Peiyu LIOU, Elizabeth Moritz HALVORSEN, Gregory MCKENZIE, Edward J. O'BRIEN, David COOK
  • HDAC6 INHIBITORS AND USES THEREOF
    Publication number: 20240174616
    Abstract: Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 30, 2024
    Applicant: Eikonizo Therapeutics, Inc.
    Inventors: Florence Fevrier Wagner, Dean Hickman
  • Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
    Publication number: 20240175047
    Abstract: Provided herein are vectors comprising a polycistronic expression casstte comprising a polynucleotide that encodes a TCR alpha chain, a polynucleotide that encodes a TCR beta chain, and a polynucleotide that encodes a cytokine, wherein the polynucleotides are separated by polynucleotide sequences that comprise 2A elements.
    Type: Application
    Filed: February 17, 2022
    Publication date: May 30, 2024
    Applicant: Alaunos Therapeutics, Inc.
    Inventors: Drew Caldwell DENIGER, Lenka Victoria HURTON, Laurence James Neil COOPER, Donghyun JOO, Yaoyao SHI, An LU, Victor CARPIO, Matthew COLLINSON-PAUTZ
  • HEPCIDIN ANALOGUES AND USES THEREOF
    Publication number: 20240174726
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: September 28, 2023
    Publication date: May 30, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie SMYTHE, Gregory Thomas BOURNE, Simone VINK, Brian Troy FREDERICK, Praveen MADALA, Anne Pernille TOFTENG SHELTON, Jacob Ulrik FOG
  • Compositions and Methods For Reducing Immune Intolerance
    Publication number: 20240173389
    Abstract: Provided herein are compositions comprising amino acids, e.g., hydroxyamino acids, thioamino acids, or pharmaceutically acceptable salts thereof, that can be used to reduce immune intolerance in a subject. The compositions can be used, for example, to treat autoimmune disorders or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy.
    Type: Application
    Filed: March 11, 2022
    Publication date: May 30, 2024
    Applicant: LAPIX THERAPEUTICS, INC.
    Inventors: Anas Fathallah, Abdulraouf Ramadan
  • STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF
    Publication number: 20240174723
    Abstract: Provided are stapled antimicrobial peptides (i.e., StAMPs) and methods of using the same (e.g., for treating bacterial infections caused by Gram-negative bacteria). In certain embodiments, the stapled peptides are based on the amino acid sequence of the antimicrobial peptide Magainin II, but include certain modifications that have been found to confer advantageous properties (e.g., improved antimicrobial activity, selectivity for killing Gram-negative bacteria, and/or reduced toxicity).
    Type: Application
    Filed: March 11, 2022
    Publication date: May 30, 2024
    Applicant: Lytica Therapeutics, Inc.
    Inventors: Rida Mourtada, Warren A. Dorsch
  • INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7)
    Publication number: 20240174632
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 30, 2024
    Applicant: Morphic Therapeutic, Inc.
    Inventors: Matthew G. BURSAVICH, Dan CUI, James E. DOWLING, Kristopher N. HAHN, Bryce A. HARRISON, Fu-Yang LIN, Blaise S. LIPPA, Bruce N. ROGERS, Dawn M. TROAST, Cheng ZHONG, Kyle D. KONZE, Aleksey I. GERASYUTO, Byungchan KIM, Salma RAFI, Tyler DAY, Eugene HICKEY, Evelyne HOUANG, Robert ZAHLER
  • Rotary pill dispenser and method of use
    Patent number: 11992465
    Abstract: An automated medication dispenser system is disclosed. The system includes a dispenser device comprising a medication dispensing and storage module, a dispensing drive and control mechanism, and a communications interface. A third party communications host is in communication with the dispenser device, and has administration software with executable instructions for control of the dispensing drive and control mechanism to dispense medication from the medication dispensing and storage module. The communications interface is in communication with the third party communications host.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: May 28, 2024
    Assignee: Zig Therapeutics, Inc.
    Inventors: Don A. Bukstein, Gary C. Steven, Joseph C. Steven
  • Trans-splicing molecules
    Patent number: 11993776
    Abstract: The present invention features nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs)) capable of correcting one or more mutations in the ABCA4 gene or the CEP290 gene. Such molecules are useful in the treatment of disorders associated with mutations in ABCA4, such as Stargardt Disease (e.g., Stargardt Disease 1) and disorders associated with a mutation in CEP290, such as Leber congenital amourosis 10 (LCA 10). Also provided by the invention described herein are methods of using the nucleic acid trans-splicing molecules for correcting mutations in ABCA4 and CEP290 and for treating disorders associated with mutations in ABCA4 and CEP290, such as Stargardt Disease and LCA 10.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: May 28, 2024
    Assignees: Ascidian Therapeutics, Inc., The Trustees of the University of Pennsylvania
    Inventors: Philip R. Johnson, Bruce C. Schnepp, Jean Bennett, Scott J. Dooley, Krishna Jawaharlal Fisher, Junwei Sun
  • Methods of treating neurological disorders
    Patent number: 11993580
    Abstract: The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: May 28, 2024
    Assignee: Neumora Therapeutics, Inc.
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
    Patent number: 11993661
    Abstract: The present application provides constructs comprising an antibody moiety that specifically binds to PSMA (e.g., PSMA expressed on the surface of a cell). Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 28, 2024
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Hong Liu, Hongruo Yun, Xiaomei Ge, Zhiyuan Yang, Lianxing Liu, Pengbo Zhang, Yixiang Xu, Shan Li, Lucas Horan
  • Transposition-based therapies
    Patent number: 11993784
    Abstract: Gene therapy compositions and methods are provided that make use of novel transposases and/or chimeric transposases for targeted transposition.
    Type: Grant
    Filed: March 29, 2023
    Date of Patent: May 28, 2024
    Assignee: Saliogen Therapeutics, Inc.
    Inventors: Joseph J. Higgins, Scott McMillan, Ray Tabibiazar